Antiprotozoal agents (ATC code: ATC P01) is a class of pharmaceuticals used in treatment of protozoan infection.

Protozoans have little in common with each other (for example, Entamoeba histolytica, an unikont eukaryotic organism, is less closely related to Naegleria fowleri, a bikont eukaryotic organism, than it is to Homo sapiens, which belongs to the unikont phylogenetic group) and so agents effective against one pathogen may not be effective against another.

They can be grouped by mechanism[1] or by organism.[2] Recent papers have also proposed the use of viruses to treat infections caused by protozoa.[3][4]



  1. Cynthia R. L. Webster (15 June 2001). Clinical pharmacology. Teton NewMedia. pp. 86–. ISBN 978-1-893441-37-8. Retrieved 2 May 2010.
  2. Anthony J. Trevor; Bertram G. Katzung; Susan B. Masters (11 December 2007). Katzung & Trevor's pharmacology: examination & board review. McGraw-Hill Professional. pp. 435–. ISBN 978-0-07-148869-3. Retrieved 2 May 2010.
  3. Keen, E. C. (2013). "Beyond phage therapy: Virotherapy of protozoal diseases". Future Microbiology. 8 (7): 821–823. doi:10.2217/FMB.13.48.
  4. Hyman, P.; Atterbury, R.; Barrow, P. (2013). "Fleas and smaller fleas: Virotherapy for parasite infections". Trends in Microbiology. 21 (5): 215–220. doi:10.1016/j.tim.2013.02.006. PMID 23540830.
This article is issued from Wikipedia - version of the 10/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.